

*February 6, 2015***AxoGen (Nasdaq/AXGN/Buy/\$3.16)***Robert M. Wasserman*

Director of Research

561-208-2905

rwasserman@dawsonjames.com

**ARCA biopharma (Nasdaq/ABIO/Buy/\$0.70)**

1) **AxoGen (Nasdaq/AXGN/Buy/\$3.16)** – AxoGen pre-released selected financial results for their Q4/2014 quarter earlier this week, including revenues of \$4.79 million, up 61% year-over-year, and for 2014 as a whole the Company posted revenues of \$16.8 million, or an increase of 54% from 2013. Our estimate had been revenues of \$4.48 million for Q4 for AxoGen, or a jump of 50%. AxoGen also related that at the close of the calendar year the Company held \$8.2 million in cash, and that they paid approximately \$0.9 million in financing expenses related to a new \$25 million credit facility signed in late 2014. AxoGen further related that they expect to report complete financial results for their Q4/2014 quarter in early March. In addition, yesterday the Company closed a \$13 million public offering of common shares, issuing 4.7 million shares at \$2.75 per share. AxoGen now has 24.2 million shares outstanding. The proceeds of the offerings are expected to provide sufficient operating capital for this year and next year as well, and potentially until the Company reaches the break-even point. We currently rate shares of AXGN a Buy with a 12-18 month price target of \$5. **RMW**

2) **ARCA biopharma (Nasdaq/ABIO/Buy/\$0.70)** – ARCA earlier this week announced the receipt of a patent on methods and compositions of the S-isomer formulation of Gencaro (bucindolol hydrochloride) from the US Patent and Trademark Office (USPTO). The patent, US #8,946,284 is entitled “Methods and Compositions involving (S)-Bucindolol” and provides intellectual property protection in the US for the use of S-isomer Gencaro, which is Gencaro substantially free of the R-stereoisomer, as a potential treatment for right ventricular heart failure, congestive heart failure, angina, myocardial infarction, cardiac arrhythmia, mitral valve prolapse, hypertrophic obstructive cardiomyopathy, or acute dissecting aortic aneurysm. The S-isomer of Gencaro contains the high affinity beta-1 and beta-2 receptor-blocking action as well as nitric oxide generating activity. ARCA currently holds patents in the US and Europe related to the use of Gencaro in patients predicted to have a favorable response to the drug based on genetic polymorphisms in the genes encoding the beta-1 and/or alpha-2C receptors, which could deter potential generic competition until 2025 or 2026. We currently rate shares of ABIO a Buy with a 12-18 month price target of \$3.75. **RMW**

Morning Notes provide current information we believe might be noteworthy to investors regarding the subject companies. Morning Notes are not intended to be complete research reports. More detailed information concerning the rated companies referenced in this Note, including the full reports, basis for price targets and other disclosures, may be found at:

<http://www.DawsonJames.com/portal.html>.

**Important Disclosures:**

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the profiled company. The Firm has received investment banking compensation from one of the company(s) profiled in this report (ABIO) and may seek compensation for investment banking services in the future from the profiled company(s). The Firm has not received other compensation from the profiled company(s) in the last 12 months.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of January 31, 2015, the firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company (s). The Firm, its officers, directors, analysts or employees may effect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the companies subject to this report. The Firm may effect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

**Ratings Definitions:**

- 1) **Buy:** the analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** the analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** the analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Ratings Distribution	Company Coverage		Investment Banking	
	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	15	71%	9	60%
Market Perform (Neutral)	6	29%	4	67%
Market Underperform (Sell)	0	0%	0	0%
Total	21	100%	13	62%

### **Analyst Certification:**

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.